A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03832998

Title field or adapter rule

{'original_value': 'A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-30T23:06:05.256774+00:00

Published At

2026-10-28T00:00:00+00:00

Record Updated At

2026-10-28

Results Posted At

2026-10-28

Source Retrieved At

2026-10-30T22:08:04.216214+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Migraine"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT03832998"

protocolSection.identificationModule.officialTitle

"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to \u003c 12 Years) and Adolescents (12 to \u003c 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

Study condition terms

• Migraine (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Dose Level 1'], 'description': 'Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.', 'name': 'Erenumab Dose 1', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Dose Level 1', 'Dose Level 2'], 'description': 'Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and participants in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.', 'name': 'Erenumab Dose 2', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Dose Level 2'], 'description': 'Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.', 'name': 'Erenumab Dose 3', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Placebo'], 'description': 'Placebo matching dose for erenumab dose 1, 2 and 3.', 'name': 'Placebo', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Erenumab Dose 1 (protocolSection.armsInterventionsModule.interventions[].name)
• Erenumab Dose 2 (protocolSection.armsInterventionsModule.interventions[].name)
• Erenumab Dose 3 (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.